{"id":57925,"date":"2021-09-20T10:38:00","date_gmt":"2021-09-20T10:38:00","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=79081"},"modified":"2021-09-20T10:38:00","modified_gmt":"2021-09-20T10:38:00","slug":"adagio-therapeutics-provides-covid-19-antibody-program-updates-as-well-as-business-highlights-and-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/adagio-therapeutics-provides-covid-19-antibody-program-updates-as-well-as-business-highlights-and-second-quarter-2021-financial-results\/","title":{"rendered":"Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results"},"content":{"rendered":"
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021<\/em><\/p>\n Patient Population in Global EVADE Phase 2\/3 Clinical Trial of ADG20 Expanded following IDMC Assessment <\/em><\/p>\n $355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential <\/em><\/p>\n WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.<\/p>\n \u201cAcross the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks,\u201d said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. \u201cOur team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.<\/p>\n \u201cADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women,\u201d said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. \u201cTo date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro <\/em>models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year\u2019s IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic.\u201d<\/p>\n ADG20 COVID-19 Program Highlights <\/em><\/strong><\/p>\n Recent Business Highlights<\/em><\/strong><\/p>\n Second Quarter 2021 Financial Results<\/strong><\/p>\n About ADG20 About Adagio Therapeutics<\/strong><\/p>\n Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company\u2019s portfolio of antibodies has been optimized using Adimab\u2019s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio\u2019s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com<\/a>.<\/p>\n Forward Looking Statements<\/strong> Contacts: <\/strong><\/p>\n Media Contact:<\/strong>\n
\n
\n
\n
\n
\n<\/strong>ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.<\/p>\n
\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cprojects,\u201d and \u201cfuture\u201d or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates.<\/em> We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading \u201cRisk Factors\u201d in Adagio\u2019s prospectus filed with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d) on August 6, 2021\u00a0and in Adagio\u2019s future reports to be filed with the\u00a0SEC, including Adagio\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.<\/em><\/p>\n
\nDan Budwick, 1AB
\nDan@1abmedia.com<\/a><\/p>\n